OEM News

RSNA 2024: Cleerly Makes its Debut with AI-Enabled Innovations in Cardiovascular Imaging

For the first time, Cleerly will attend RSNA highlighting its AI-QCT and other technologies.

Author Image

By: Rachel Klemovitch

Assistant Editor

Cleerly, a leader in advanced cardiovascular imaging, will participate in the Radiological Society of North America (RSNA) Conference and Annual Meeting, taking place from December 1 to 5, 2024, at McCormick Place Convention Center in Chicago, Illinois. 

Cleerly software is an AI-enabled digital care platform to support physicians in identifying and defining heart disease by analyzing non-invasive CCTA images. The company supports precision diagnostics through sub-millimeter quantification and characterization of atherosclerosis, or plaque build-up in the heart arteries.

At RSNA, Cleerly leadership will provide live demonstrations of the company’s AI-enabled coronary computed tomography angiography (CCTA) solution to help guide personalized prognosis, diagnosis, and treatment of coronary artery disease (CAD).

Cleerly’s AI-Quantitative Coronary CT (AI-QCT) technology, Cleerly Labs, in several studies comparing it with invasive gold standards, has been demonstrated to be highly accurate in the assessment of the presence, extent, and composition of coronary atherosclerotic plaque and similar to consensus readings of Level 3 Expert Physician Readers. 

Cleerly ISCHEMIA, an additional AI-enabled product, has also been proven to demonstrate high diagnostic performance compared to invasive fractional flow reserve (FFR) and higher performance than such legacy tests as nuclear SPECT imaging and FFRCT.

Last month, five Medicare Administrative Contractors officially approved AI-QCT scans for Medicare recipients exhibiting stable and acute symptoms suspicious of coronary artery disease. The new Medicare coverage will include Cleerly Labs Plaque Analysis for patients with acute or stable chest pain and no known CAD, as well as CAD-RADS 1-3.

The American Medical Association also recently approved a permanent CPT Category I code for Cleerly’s AI-QCT advanced plaque analyses, effective January 1, 2026.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters